Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia a baseline from the GLORIA Registry

Aim: To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden. Patients & methods: Post hoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and >= 4 h/day of levodopa-induced dyskinesia at baseline. Results & conclusions: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with >= 4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1.6 h in patients with <4 h baseline dyskinesia. Quality of life improved in both subgroups. Adverse drug reactions occurred at similar rates in both subgroups. Despite increases in levodopa dose, levodopa-carbidopa intestinal gel treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson's disease patients with high baseline dyskinesia burden.